+Vote!
Fiercebiotech (Free subscription) | yesterday
Just three weeks out of the gate , Redwood City, CA-based Facet Biotech has announced a new restructuring plan. The PDL BioPharma spin-off says it has completed its strategic business review and it will be implementing cost-cutting measures, including cutting its workforce by 80 positions across the organization. The company also plans to consolidate operations into one of two buildings it currently...
+Vote!
Market Wire (Free subscription) | 01/06/2009
INCLINE VILLAGE, NV (MARKET WIRE) PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (Notes). The conversion rate, as adjusted, is 82.162 shares of common stock per $1,000 principal amount of the Notes, effective January 5, 2009. The conversion rate for the Notes was previously 61.426 shares of...
1Vote!
Xconomy (Free subscription) | 01/05/2009
Alexion Pharmaceuticals (NASDAQ:ALXN) reports it will pay $25 million to PDL BioPharma (NASDAQ:PDLI) to license a patent related to humanizing antibodies and to settle a legal dispute between the two companies. Cheshire, CT-based Alexion says the license enables the firm to commercialize its humanized antibody eculizumab (Soliris)—now approved to treat a rare blood disorder called [...]
1Vote!
PR News Wire (Free subscription) | 01/05/2009
Alexion Licenses PDL's Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: ) and Alexion Pharmaceuticals, Inc. (Nasdaq: ) today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized...
+Vote!
Fiercebiotech (Free subscription) | 12/22/2008
PDL BioPharma has spun off its biotech business into Facet Biotech Corp. Facet will be based in PDL's Redwood City, CA offices while the rest of the company moves to Incline Village, NV. Facet was formed after a group of the company's biggest shareholders mounted a revolt against the company's management that led to the departure of CEO Mark McDade. Report
+Vote!
Pharmalot (Free subscription) | 12/19/2008
Here’s one way to shorten your commute. PDL BioPharma has just moved its headquarters from Redwood City, California, to Incline Village, Nevada, a Lake Tahoe resort community known as a destination for Californians looking to escape high tax rates (check out the activities). And guess who lives there? A John P. McLaughlin is listed as a [...]
1Vote!
Market Wire (Free subscription) | 12/18/2008
INCLINE VILLAGE, NV (MARKET WIRE) PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has appointed Christine Larson, CPA, as its vice president and chief financial officer (CFO). Larson brings more than 20 years of experience as a financial professional to the role.
+Vote!
Market Wire (Free subscription) | 12/09/2008
REDWOOD CITY, CA (MARKET WIRE) PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that the Securities and Exchange Commission (SEC) has declared effective the Form 10 registration statement filed by PDL's wholly owned subsidiary, Facet Biotech Corporation.
1Vote!
Market Wire (Free subscription) | 12/05/2008
REDWOOD CITY, CA (MARKET WIRE) PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has reset the record date for the spin-off of PDL's biotechnology operations, which will be accomplished through a pro rata stock dividend to PDL's stockholders of the common stock of Facet Biotech Corporation, to December 5, 2008.
1Vote!
Market Wire (Free subscription) | 12/04/2008
REDWOOD CITY, CA (MARKET WIRE) PDL BioPharma, Inc. (NASDAQ: PDLI) today announced the election of David Parkinson, M.D., as a member of the board of directors of Facet Biotech Corporation, the biotechnology company PDL plans to spin off into a separate, publicly-held company, effective on or about December 18, 2008.
+Vote!
The San Francisco Business Times (Free subscription) | 11/19/2008
PDL BioPharma Inc. could spin off its biotech operations into Facet Biotech Corp. by Dec. 18. (PDLI) (DNA) (ANSV) (BIIB)
+Vote!
Market Wire (Free subscription) | 11/19/2008
REDWOOD CITY, CA (MARKET WIRE) PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that its board of directors has set December 3, 2008 as the record date for the spin-off of PDL's biotechnology operations, which will be accomplished through a pro rata stock dividend to PDL's stockholders of the common stock of Facet Biotech Corporation. Each PDL stockholder of record as of 5:00 p.m. Eastern Time...
1Vote!
The East Bay Business Times (Free subscription) | 11/10/2008
PDL BioPharma Inc. named John McLaughlin as president and CEO following the company’s spinoff of its biotech assets. (PDLI) (ANSV) (DNA) (WYE)
